Sandra Verploegen

2.4k citations

27 papers · 1.6k indexed · h-index 16

Hematology top 2%
Radiology, Nuclear Medicine and Imaging top 2%
- Monoclonal and Polyclonal Antibodies Research 17
- Radiopharmaceutical Chemistry and Applications 2
Oncology top 5%
- HER2/EGFR in Cancer Research 6
- CAR-T cell therapy research 4
- Cytokine Signaling Pathways and Interactions 3
Immunology top 5%
Genetics top 5%
- Chronic Lymphocytic Leukemia Research 4
Immunology and Allergy
- Cell Adhesion Molecules Research 7
Molecular Biology
- Glycosylation and Glycoproteins Research 4

Co-authors: Paul W.H.I. Parren Wim K. Bleeker Marije B. Overdijk Esther C.W. Breij Janine Schuurman Jeroen J. Lammerts van Bueren Marjolein van Egmond Richard W.J. Groen
Cited by: Hematology Radiology, Nuclear Medicine and Imaging Oncology
Journals: Proceedings of the National Academy of Sciences (1 paper)Journal of Clinical Oncology (3 papers)Blood (7 papers)
Partner nations: Netherlands United States Denmark

In The Last Decade

Sandra Verploegen

27 papers receiving 1.6k citations

Peers

Countries citing papers authored by Sandra Verploegen

Since Specialization

Citations

This map shows the geographic impact of Sandra Verploegen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Verploegen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Verploegen more than expected).

Fields of papers citing papers by Sandra Verploegen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra Verploegen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Verploegen. The network helps show where Sandra Verploegen may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Sandra Verploegen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sandra Verploegen Line = papers co-authored together Sandra Verploegen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Logic-gated antibody pairs that selectively act on cells co-expressing two antigens Nature Biotechnology ·Simone C. Oostindie,Derek A. Rinaldi,Gijs G. Zom,Michael J. Wester,Desiree Paulet,Kusai Al-Tamimi,Els van der Meijden,Jennifer R. Scheick,Tessa Wilpshaar,Bart de Jong,Marloes Hoff-van den Broek,Rachel M. Grattan,Janita J. Oosterhoff,Julie Vignau,Sandra Verploegen,Péter Boross,Frank J. Beurskens,Diane S. Lidke,Janine Schuurman,Rob N. de Jong	2022	31
2	Epidermal Growth Factor Receptor as Target for Perioperative Elimination of Circulating Colorectal Cancer Cells Journal of Oncology ·Mandy Gruijs,Rens Braster,Marije B. Overdijk,Tessa Hellingman,Sandra Verploegen,Rianne Korthouwer,Berend J. van der Wilk,Paul W.H.I. Parren,Hans van Vliet,Marijn Bögels,Marjolein van Egmond	2022	8
3	DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing EBioMedicine ·Patrick Engelberts,Ida H. Hiemstra,Bart de Jong,Danita H. Schuurhuis,Joyce Meesters,Irati Beltrán Hernández,Simone C. Oostindie,Joost Neijssen,Edward N. van den Brink,G. Jean Horbach,Sandra Verploegen,Aran F. Labrijn,Theodora W. Salcedo,Janine Schuurman,Paul W.H.I. Parren,Esther C.W. Breij	2020	102
4	Abstract 221: Tisotumab vedotin induces anti-tumor activity through MMAE-mediated, Fc-mediated, and Fab-mediated effector functions in vitro Cancer Research ·Stephen C. Alley,Jeffrey Harris,Anthony Cao,Elke Gresnigt-Van den Heuvel,Jyoti Velayudhan,David Satijn,Sandra Verploegen,Teresa Dominguez,Esther C.W. Breij	2019	17
5	Abstract 221: Tisotumab vedotin induces anti-tumor activity through MMAE-mediated, Fc-mediated, and Fab-mediated effector functionsin vitro Stephen C. Alley,Jeffrey R. Harris,Anthony Cao,Elke Gresnigt-Van den Heuvel,Jyoti Velayudhan,David Satijn,Sandra Verploegen,Teresa Dominguez,Esther C.W. Breij	2019	1
6	PS1301 POTENT ANTI‐TUMOR ACTIVITY OF DUOBODY^®‐CD3XCD20 IN PRECLINICAL MODELS IN VITRO AND IN VIVO HemaSphere ·Ida H. Hiemstra,Patrick Engelberts,Bart de Jong,Danita H. Schuurhuis,Theodora W. Salcedo,Sandra Verploegen,M. van der Zee,P.A. Usher,Edward van den Brink,K. Sasser,Paul W.H.I. Parren,Aran F. Labrijn,Janine Schuurman,Esther C.W. Breij	2019	1
7	CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory Molecular Cancer Therapeutics ·Hreinn Benonisson,Işıl Altıntaş,Marjolein Sluijter,Sandra Verploegen,Aran F. Labrijn,Danita H. Schuurhuis,Mischa Houtkamp,J. Sjef Verbeek,Janine Schuurman,Thorbald van Hall	2018	61
8	Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models Scientific Reports ·Aran F. Labrijn,Joyce Meesters,Matthew W. Bunce,Anthony A. Armstrong,Sandeep Somani,Tom Nesspor,Mark L. Chiu,Işıl Altıntaş,Sandra Verploegen,Janine Schuurman,Paul W.H.I. Parren	2017	31
9	A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface PLoS Biology ·Rob N. de Jong,Frank J. Beurskens,Sandra Verploegen,Kristin Strumane,Muriel D. van Kampen,Marleen Voorhorst,Wendy Horstman,Patrick Engelberts,Simone C. Oostindie,Guanbo Wang,Albert J. R. Heck,Janine Schuurman,Paul W.H.I. Parren	2016	153
10	Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma mAbs ·Marije B. Overdijk,Sandra Verploegen,Marijn Bögels,Marjolein van Egmond,Jeroen J. Lammerts van Bueren,Tuna Mutis,Richard W.J. Groen,Esther C.W. Breij,Anton C. Martens,Wim K. Bleeker,Paul W.H.I. Parren	2015	370
11	Preclinical efficacy studies using HuMax-Axl-ADC, a novel antibody-drug conjugate targeting Axl-expressing solid cancers. Journal of Clinical Oncology ·Esther C.W. Breij,Sandra Verploegen,Andreas Lingnau,Edward N. van den Brink,Maarten L. Janmaat,Mischa Houtkamp,Wim K. Bleeker,David Satijn,Paul W.H.I. Parren	2015	6
12	An Antibody–Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors Cancer Research ·Esther C.W. Breij,Bart E.C.G. de Goeij,Sandra Verploegen,Danita H. Schuurhuis,Ali Amirkhosravi,John Francis,Vibeke Breinholt Miller,Mischa Houtkamp,Wim K. Bleeker,David Satijn,Paul W.H.I. Parren	2013	166
13	Crosstalk between Human IgG Isotypes and Murine Effector Cells The Journal of Immunology ·Marije B. Overdijk,Sandra Verploegen,Antonio Ortiz Buijsse,Tom Vink,Jeanette H.W. Leusen,Wim K. Bleeker,Paul W.H.I. Parren	2012	157
14	Phagocytosis Is A Mechanism of Action for Daratumumab Blood ·Marije B. Overdijk,Sandra Verploegen,Bögels Marijn,Marjolein van Egmond,Richard W.J. Groen,Anton C. Martens,Jeroen Lammerts van Bueren,Wim K. Bleeker,Paul W.H.I. Parren	2012	12
15	Characterization of the role of CaMKI-like kinase (CKLiK) in human granulocyte function Blood ·Sandra Verploegen,Laurien H. Ulfman,Hanneke W. M. van Deutekom,Corneli van Aalst,Henk Honing,Jan‐Willem J. Lammers,Leo Koenderman,Paul J. Coffer	2005	39
16	Role of Ca²⁺/calmodulin regulated signaling pathways in chemoattractant induced neutrophil effector functions European Journal of Biochemistry ·Sandra Verploegen,Caroline M. van Leeuwen,Hanneke W. M. van Deutekom,Jan‐Willem J. Lammers,Leo Koenderman,Paul J. Coffer	2002	26
17	Identification of cytokine-regulated genes in human leukocytes in vivo Journal of Allergy and Clinical Immunology ·Cornelieke M.E.G. Pals,Sandra Verploegen,Jan A. M. Raaijmakers,Jan‐Willem J. Lammers,Leo Koenderman,Paul J. Coffer	2000	9
18	Identification and characterization of CKLiK, a novel granulocyte Ca++/calmodulin-dependent kinase Blood ·Sandra Verploegen,Jan‐Willem J. Lammers,Leo Koenderman,Paul J. Coffer	2000	32
19	Identification and characterization of CKLiK, a novel granulocyte Ca++/calmodulin-dependent kinase Blood ·Sandra Verploegen,Jan‐Willem J. Lammers,Leo Koenderman,Paul J. Coffer	2000	2
20	A human leptin mutant induces weight gain in normal mice FEBS Letters ·Sandra Verploegen,Geert Plaetinck,René Devos,José Van der Heyden,Yves Guisez	1997	63

About Sandra Verploegen

Sandra Verploegen is a scholar working on Immunology and Allergy, Radiology, Nuclear Medicine and Imaging and Oncology, having authored 27 papers that have together received 1.6k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (17 papers), Cell Adhesion Molecules Research (7 papers), HER2/EGFR in Cancer Research (6 papers), Glycosylation and Glycoproteins Research (4 papers), Chronic Lymphocytic Leukemia Research (4 papers), CAR-T cell therapy research (4 papers), Cytokine Signaling Pathways and Interactions (3 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). The work is most often cited by research in Hematology (368 citations), Radiology, Nuclear Medicine and Imaging (729 citations) and Oncology (709 citations). Sandra Verploegen has collaborated with scholars based in Netherlands, United States and Denmark. Frequent co-authors include Paul W.H.I. Parren, Wim K. Bleeker, Marije B. Overdijk, Esther C.W. Breij, Janine Schuurman, Jeroen J. Lammerts van Bueren, Marjolein van Egmond, Richard W.J. Groen, Anton C. Martens and Marijn Bögels. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact